Genflow Biosciences (GENF) Competitors

GBX 2.19

+0.02 (+0.69%)

(As of 10:07 AM ET)

GENF vs. SAR, AREC, SBTX, OKYO, HEMO, AOR, OPTI, OBI, ONC, and RLM

Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include Sareum (SAR), Arecor Therapeutics (AREC), SkinBioTherapeutics (SBTX), OKYO Pharma (OKYO), Hemogenyx Pharmaceuticals (HEMO), AorTech International (AOR), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), Oncimmune (ONC), and Realm Therapeutics (RLM). These companies are all part of the "biotechnology" industry.

Genflow Biosciences vs.

Sareum (LON:SAR) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

: Genflow Biosciences' return on equity of -105.34% beat Sareum's return on equity.
Company Net Margins Return on Equity Return on Assets
Sareum N/A -257.72% -113.80%
Genflow Biosciences N/A -105.34% -55.19%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sareum
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Genflow Biosciences
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Genflow Biosciences has lower revenue, but higher earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sareum £47.20K 594.59 -£4.25M -£0.06 -433.33
Genflow Biosciences N/A N/A -£1.63M -£0.01 -219.00
: In the previous week, Sareum had 2 more articles in the media than Genflow Biosciences. MarketBeat recorded 2 mentions for Sareum and 0 mentions for Genflow Biosciences. Sareum's average media sentiment score of 0.32 beat Genflow Biosciences' score of 0.00 indicating that Sareum is being referred to more favorably in the media.
Company Overall Sentiment
Sareum Neutral
Genflow Biosciences Neutral
: 9.2% of Genflow Biosciences shares are held by institutional investors. 5.0% of Sareum shares are held by company insiders. Comparatively, 64.2% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Sareum received 82 more outperform votes than Genflow Biosciences when rated by MarketBeat users.
Company Underperform Outperform
Sareum Outperform Votes
82
66.13%
Underperform Votes
42
33.87%
Genflow Biosciences N/A N/A
: Sareum has a beta of -1.08, meaning that its stock price is 208% less volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Sareum	N/A	-257.72%	-113.80%
Genflow Biosciences	N/A	-105.34%	-55.19%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sareum	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Genflow Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sareum	£47.20K	594.59	-£4.25M	-£0.06	-433.33
Genflow Biosciences	N/A	N/A	-£1.63M	-£0.01	-219.00

Company	Overall Sentiment
Sareum	Neutral
Genflow Biosciences	Neutral

Company	Underperform	Outperform
Sareum	Outperform Votes 82 66.13%	Underperform Votes 42 33.87%
Genflow Biosciences	N/A	N/A

Summary

Genflow Biosciences beats Sareum on 8 of the 12 factors compared between the two stocks.

Ad Insiders Exposed

Has Trump Finally Gone Too Far?

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Get Genflow Biosciences News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENF vs. The Competition

Export to Excel

Metric	Genflow Biosciences	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£7.66M	£263.32M	£5.69B	£1.41B
Dividend Yield	N/A	3.31%	4.94%	11.72%
P/E Ratio	-219.00	324.62	147.31	1,624.40
Price / Sales	N/A	11,388.77	1,677.53	173,530.46
Price / Cash	3.00	12.23	37.14	32.91
Price / Book	N/A	7.06	4.92	2.83
Net Income	-£1.63M	-£32.19M	£115.11M	£152.73M
7 Day Performance	-4.37%	-0.19%	6.94%	0.03%
1 Month Performance	-4.78%	4.95%	7.65%	-1.03%
1 Year Performance	6.83%	11.98%	31.96%	86.81%

Genflow Biosciences Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SAR Sareum	0 of 5 stars 0.00 / 5 stars	GBX 27 -3.6%	N/A	-66.5%	£29.15M	£47,204.00	-450.00	3,211	Gap Down
AREC Arecor Therapeutics	0 of 5 stars 0.00 / 5 stars	GBX 72.03 -10.0%	N/A	-59.5%	£27.20M	£4.57M	-257.23	10	Gap Up
SBTX SkinBioTherapeutics	0 of 5 stars 0.00 / 5 stars	GBX 10.50 -11.6%	N/A	-52.2%	£23.74M	£21,949.00	-525.00	11	News Coverage Gap Down High Trading Volume
OKYO OKYO Pharma	0 of 5 stars 0.00 / 5 stars	N/A	N/A	+0.0%	£23.24M	N/A	-140.00	7	News Coverage Gap Down
HEMO Hemogenyx Pharmaceuticals	0 of 5 stars 0.00 / 5 stars	GBX 1.52 -3.7%	N/A	-42.4%	£20.31M	N/A	-151.60	14	Positive News Gap Down
AOR AorTech International	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	£19.99M	£539,000.00	-33.38	3
OPTI OptiBiotix Health	0 of 5 stars 0.00 / 5 stars	GBX 17.78 +3.1%	N/A	-24.2%	£17.41M	£1.26M	-889.00	1
OBI Ondine Biomedical	0 of 5 stars 0.00 / 5 stars	GBX 5.75 -2.1%	N/A	-45.0%	£15.94M	£1.20M	-143.75	N/A
ONC Oncimmune	0 of 5 stars 0.00 / 5 stars	GBX 18.67 -3.3%	N/A	+5.1%	£13.84M	£1.21M	-622.40	52	Gap Up
RLM Realm Therapeutics	0 of 5 stars 0.00 / 5 stars	GBX 11.50 flat	N/A	+0.0%	£13.41M	£501,919.00	-0.66	N/A	Negative News